Title
OBI Pharma OBI-999-001 Advaned solid tumors GLOBO-H positive
Study Title
A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients With Advanced Solid Tumors
Malignancy
Pancreatic, Esophageal, Gastric, Colorectal, Breast, Lung, Prostate, Melanoma, Head and Neck, Sarcoma, Bladder, Renal Cell, Ovarian, Endometrial, Cervical
Key Eligibility Criteria Details
- Histologically or cytologicall confirmed patients with advanced solid tumors
- Must have documented Globo H score of at least 100 from a qualified laboratory IHC assay
- Must have been treated with established standard-f-care therapy or physicians have determined that such established therapy is not sufficiently efficacious or patients have declined to received standard-of-care therapy
- ECOG PS 0-1
- Measurable disease
- Adequate organ function
- No known untreated CNS mets
- No significant clinical cardiac abnormality